Alken Asset Management Ltd Makes New $670,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

Alken Asset Management Ltd purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,000 shares of the medical device company’s stock, valued at approximately $670,000. DexCom makes up about 1.3% of Alken Asset Management Ltd’s portfolio, making the stock its 27th biggest holding.

A number of other hedge funds have also recently made changes to their positions in the business. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the 2nd quarter worth approximately $25,000. Sachetta LLC grew its holdings in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the last quarter. Crewe Advisors LLC purchased a new position in shares of DexCom in the first quarter worth $29,000. Riverview Trust Co bought a new stake in DexCom during the 1st quarter valued at $32,000. Finally, DT Investment Partners LLC boosted its position in DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after buying an additional 315 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at approximately $4,607,617.95. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,824 shares of company stock worth $126,390 over the last three months. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Stifel Nicolaus upped their price objective on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, August 23rd. Canaccord Genuity Group restated a “buy” rating and set a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. UBS Group dropped their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Wells Fargo & Company dropped their price target on DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $110.69.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $69.21 on Monday. The company has a 50 day simple moving average of $70.17 and a two-hundred day simple moving average of $102.36. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a market capitalization of $27.52 billion, a price-to-earnings ratio of 44.65, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $1.04 billion. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter last year, the company earned $0.34 EPS. Analysts expect that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.